RxDoctor Payments Data

Martha Ridley, APRN

Family · Henderson, KYNPI 1720410327

Payments from drug & device makers

$3,997in general payments, 2019–2025

Across 254 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$969
  • Novo Nordisk$361
  • Lilly USA, LLC$313
  • Pfizer$309
  • GSK$207
  • Otsuka America Pharmaceutical, Inc.$151
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$3,997100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,997 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$29,486
Medicare patients
127
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$48,704
EliquisApixaban50$46,399
JardianceEmpagliflozin36$37,667
RexultiBrexpiprazole16$23,050
JanuviaSitagliptin Phosphate16$21,597
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$15,575
Breo ElliptaFluticasone/Vilanterol22$14,772
FarxigaDapagliflozin Propanediol20$14,752
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,256
ViberziEluxadoline12$9,251
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,420
Potassium Chloride51$6,242
Combivent RespimatIpratropium/Albuterol Sulfate12$5,767
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen303$5,554
Mesalamine ErMesalamine12$3,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat$80$49,85462 claims
Novo NordiskOzempic$361$48,70450 claims
PfizerEliquis$309$46,39950 claims
AstraZenecaBreztri Aerosphere, Farxiga$41$30,32737 claims
GSKBreo Ellipta, Trelegy Ellipta$207$29,02844 claims
Otsuka America Pharmaceutical, Inc.Rexulti$151$23,05016 claims
MerckJanuvia$33$21,59716 claims
AbbVieViberzi, Synthroid$969$10,30440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Henderson

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →